Previous close | 278.97 |
Open | 281.57 |
Bid | 278.44 x 13700 |
Ask | 278.50 x 21700 |
Day's range | 278.27 - 282.98 |
52-week range | 228.65 - 312.99 |
Volume | |
Avg. volume | 720,376 |
Market cap | 134.562B |
Beta (5Y monthly) | 0.29 |
PE ratio (TTM) | 35.34 |
EPS (TTM) | 7.88 |
Earnings date | 13 Feb 2024 |
Forward dividend & yield | 3.81 (1.37%) |
Ex-dividend date | 11 Mar 2024 |
1y target est | 303.00 |
First non-immunosuppressive therapy for the treatment of IgA nephropathy (IgAN) approved in Europe Conditional marketing authorization is based on statistically significant and clinically meaningful results from the Phase 3 PROTECT Study SAN DIEGO, April 24, 2024 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc., (Nasdaq: TVTX) and CSL Vifor today announced that the European Commission has granted conditional marketing authorization (CMA) for FILSPARI (sparsentan) for the treatment of adults with p
CSL Vifor and Travere Therapeutics, Inc., (NASDAQ: TVTX) today announced that the European Commission has granted conditional marketing authorization (CMA) for FILSPARI (sparsentan) for the treatment of adults with primary IgAN with a urine protein excretion ≥1.0 g/day (or urine protein-to-creatinine ratio ≥0.75 g/g). The CMA is granted for all member states of the European Union, as well as in Iceland, Liechtenstein and Norway.
CSL's (ASX:CSL) stock is up by 1.2% over the past month. We wonder if and what role the company's financials play in...